Recombinant activated factor VII (rFVIIa) in refractory haemorrhage for non-haemophiliacs: an eleven-year single-centre experience

Autor: Soon Eu Chong, Mohd Hasyizan Hassan, Nizuwan Azman, Jo Anne Lim, Siti Mardhiana Mohamad, Khairul Bariah Johan, Mohd Zulfakar Mazlan, Siti Salmah Noordin, Zainab Abdul Ghaffar, Syahirah Mohamed Yusoff, Nur Arzuar Abdul Rahim, Nurfatin Mohd Shah, Muhammad Azrul Zabidi
Jazyk: angličtina
Rok vydání: 2018
Předmět:
Zdroj: BMC Hematology, Vol 18, Iss 1, Pp 1-6 (2018)
BMC Hematology
ISSN: 2052-1839
Popis: Background Massive bleeding is one of the commonest salvageable causes of death. The search for an ideal haemostatic agent during massive bleeding is still ongoing. One of the novel haemostatic medications is recombinant activated factor VII (rFVIIa). To date, the usage of rFVIIa during massive haemorrhage among non-haemophiliac patients remains off-label. The aim of this study is to report our experience in using rFVIIa to treat refractory bleeding. Methods Medical records of all patients treated with rFVIIa for massive bleeding over an eleven-year period in a single institution were recorded. Treatment indications, 24-h and 30-day mortality, changes in transfusion needs and coagulation profiles after rFVIIa administration were analysed. Results rFVIIa were administered in 76 patients. Of these, 41 (53.9%) were non-surgical bleeding, followed by 22 patients (28.9%) with trauma, other surgery bleedings in 9 patients (11.8%) and 4 patients (5.4%) with peripartum haemorrhage. Total survival rate was 78.9% within 24 h and 44.7% over 30 days. Among all these patients who had received rFVIIa due to life-threatening haemorrhage, blood and blood product requirements were significantly reduced (P
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje